PROTAC

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules that hijack the intracellular ubiquitin–proteasome system (UPS) to selectively destroy disease-causing proteins. Conceptualized in 2001 by Craig Crews, Raymond Deshaies, Kathleen Sakamoto, and colleagues, a PROTAC consists of three covalently joined modules: a warhead ligand that binds a protein of interest (POI), an E3 ligase-recruiting ligand (commonly targeting Cereblon [CRBN] or von Hippel–Lindau [VHL]), and a chemical linker of 5 to 20 atoms separating the two pharmacophores. By simultaneously engaging both the target protein and an E3 ubiquitin ligase, a PROTAC induces a productive ternary complex (POI–PROTAC–E3) that brings the target into spatial proximity with an E2–ubiquitin conjugating enzyme.

Within pharmacology and structure-based drug design, targeted protein degradation (TPD)—encompassing both heterobifunctional PROTACs and monovalent molecular glue degraders—shifts therapeutic intervention from classical occupancy-driven pharmacology to event-driven catalytic pharmacology. Whereas conventional small-molecule inhibitors must continuously occupy ≥80–90% of an enzyme's active site to block downstream signaling, a single PROTAC molecule catalyzes the polyubiquitination and 26S proteasomal destruction of multiple target molecules sequentially, opening the "undruggable" proteome (including transcription factors, scaffolding proteins, and mutated kinase resistance variants) to pharmacological clearance.

Binary vs. Ternary Equilibria and Positive Cooperativity (α > 1)

Unlike conventional drug design governed by binary binding affinity (K_d,binary) in molecular docking, PROTAC efficacy is governed by the three-body thermodynamic equilibrium of ternary complex formation (POI–PROTAC–E3). When a PROTAC binds either the POI first (with dissociation constant K_d,P) or the E3 ligase first (K_d,E), binding of the third partner to form the ternary complex is modulated by the dimensionless cooperativity factor (α):

where ΔG_ppi represents the free energy of de novo protein–protein interactions (and linker conformational entropy change) induced across the newly formed POI–E3 interface. When α > 1 (positive cooperativity, resolved crystallographically by Alessio Ciulli and colleagues in 2017 for the BRD4–MZ1–VHL complex, where α ≈ 18), favorable hydrophobic and electrostatic contacts between the POI and E3 stabilize the ternary complex well beyond the binary affinity of the warhead alone. Conversely, when α < 1 (negative cooperativity), steric clashes between the two proteins oppose complex assembly, though potent degradation can still occur if binary affinities and intracellular permeability remain high.

The High-Dose Hook Effect and Bell-Shaped Concentration Curves

A signature quantitative feature of heterobifunctional three-body equilibria is the high-dose hook effect (prozone phenomenon). At low to intermediate concentrations, increasing [PROTAC] drives accumulation of the catalytically active ternary species [POI–PROTAC–E3]. However, when free [PROTAC] rises substantially above both K_d,P and K_d,E, excess free degrader saturates the target protein and E3 ligase independently, partitioning the system into unproductive binary complexes ([POI–PROTAC] + [PROTAC–E3]) that cannot dimerize. Consequently, dose–response plots of ternary complex concentration and protein degradation follow a bell-shaped curve unless positive cooperativity (α >> 1) broadens the concentration plateau. Degrader potency is quantified by DC₅₀ (the concentration producing 50% target depletion) and D_max (the maximum percentage of protein degraded at the trough of the curve).

Hijacking Cullin-RING Ligases: CRBN, VHL, IAP, and MDM2

Although the human genome encodes more than 600 putative E3 ubiquitin ligases, clinical and preclinical PROTACs predominantly recruit substrate receptors of Cullin-RING E3 ubiquitin ligases (CRLs):

• Cereblon (CRBN, CRL4^CRBN): Recruited by immunomodulatory imide drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide, which bind a conserved tri-tryptophan cage (Trp380, Trp386, Trp400) via their glutarimide ring.
• von Hippel–Lindau (VHL, CRL2^VHL): Recruited by peptidomimetic hydroxyproline ligands (such as VH032 and VH298) that mimic the hydroxylated oxygen-dependent degradation domain of hypoxia-inducible factor 1α (HIF-1α).
• cIAP1/XIAP and MDM2: Recruited by bestatin/LCL161 derivatives (SNIPERs) or imidazoline nutlin-3a analogs, respectively, alongside emerging covalent recruiters for DCAF16, DCAF11, RNF114, and KEAP1.

Surface Lysine Accessibility, K48-Ubiquitin Chains, and Catalytic Turnover

Once the POI–PROTAC–CRL ternary complex assembles, the flexible Cullin scaffold positions an E2–ubiquitin thioester conjugate within the ubiquitination zone of the target protein. The E2 enzyme transfers ubiquitin onto solvent-exposed ε-amino groups of surface lysine (Lys) residues on the POI, followed by processive elongation of Lys48-linked (K48) or branched K11/K48 polyubiquitin chains (≥4 ubiquitin monomers). The polyubiquitinated POI then dissociates from the ternary complex and is recognized by the 19S regulatory particle of the 26S proteasome, where ATP-dependent unfoldases (Rpt1–Rpt6) thread the polypeptide into the 20S core particle for proteolytic cleavage into short peptides. Meanwhile, the unmodified PROTAC molecule is released intact to initiate another round of ternary complex assembly, maintaining pharmacodynamic suppression until the cell synthesizes new target protein via transcription and translation.

Molecular Glues and Beyond-Rule-of-Five (bRo5) Oral Bioavailability

Unlike bivalent PROTACs, molecular glue degraders (such as lenalidomide and pomalidomide) are low-molecular-weight monovalent compounds (250–450 Da) that display negligible binary affinity for the target protein in isolation. Instead, binding of lenalidomide to CRBN remodels the ligase's molecular surface, creating a composite hydrophobic hotspot that recruits zinc-finger β-hairpin G-loop degrons on neosubstrates such as the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos) or casein kinase 1α (CK1α), driving therapeutic efficacy in multiple myeloma and del(5q) myelodysplastic syndrome.

Because heterobifunctional PROTACs have molecular weights of 700 to 1,100 Da, high topological polar surface area (TPSA > 140 Ų), and numerous rotatable bonds, they reside in beyond-Rule-of-Five (bRo5) chemical space. Orally bioavailable clinical degraders—such as vepdegestrant (ARV-471) targeting the estrogen receptor (ER) in breast cancer and bavdegalutamide (ARV-110) targeting the androgen receptor (AR) in prostate cancer in clinical trial phases—achieve passive membrane permeability through molecular chameleonicity: collapsing into intramolecularly hydrogen-bonded conformations in nonpolar lipid bilayers while extending in aqueous cytosol.

How do PROTACs differ from traditional small-molecule enzyme inhibitors?

Traditional small-molecule inhibitors act by occupancy-driven pharmacology: they must bind an active site or allosteric pocket stoichiometrically (1:1) to block catalytic activity, requiring high sustained plasma concentrations and failing against non-enzymatic scaffolding proteins. PROTACs operate via event-driven catalytic pharmacology: a transient binding event anywhere on the target surface suffices to induce polyubiquitination and proteasomal destruction, eliminating both enzymatic and scaffolding functions at sub-stoichiometric doses.

What is the hook effect in PROTAC dose–response experiments, and how does cooperativity affect it?

The hook effect occurs at high PROTAC concentrations when excess free degrader independently saturates both the target protein and the E3 ubiquitin ligase, forming separate binary complexes (POI–PROTAC and PROTAC–E3) that competitively block productive ternary complex (POI–PROTAC–E3) formation. High positive cooperativity (α >> 1)—achieved when the linker geometry induces favorable de novo protein–protein contacts between the target and E3—stabilizes the ternary state and shifts the onset of the hook effect to much higher concentrations.

How does a PROTAC differ from a molecular glue degrader?

A PROTAC is a modular heterobifunctional molecule (700–1,100 Da) consisting of two distinct ligands connected by a chemical linker; the target-binding warhead possesses measurable binary affinity for the target protein on its own. A molecular glue degrader (such as lenalidomide or indisulam, 250–500 Da) is a compact monovalent molecule that binds the E3 ligase surface and allosterically or sterically creates a composite interface to capture a neosubstrate that has almost zero binary affinity for the small molecule alone.

1. Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001). "Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation." Proceedings of the National Academy of Sciences, 98(15), 8554–8559. https://doi.org/10.1073/pnas.141230798
2. Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017). "Structural basis of PROTAC cooperative recognition for selective protein degradation." Nature Chemical Biology, 13(5), 514–521. https://doi.org/10.1038/nchembio.2329
3. Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., Zinn, N., Grandi, P., Shimamura, S., Bergamini, G., Faelth-Savitski, M., Bantscheff, M., Cox, C., Gordon, D. A., Willard, R. R., Flanagan, J. J., Casillas, L. N., Votta, B. J., den Besten, W., Famm, K., Kruidenier, L., Carter, P. S., Harling, J. D., Churcher, I., & Crews, C. M. (2015). "Catalytic in vivo protein knockdown by small-molecule PROTACs." Nature Chemical Biology, 11(8), 611–617. https://doi.org/10.1038/nchembio.1858
4. Békés, M., Langley, D. R., & Crews, C. M. (2022). "PROTAC targeted protein degraders: the past is prologue." Nature Reviews Drug Discovery, 21(3), 181–200. https://doi.org/10.1038/s41573-021-00371-6